GEN Exclusives

More »

GEN News Highlights

More »
Mar 31, 2010

Veritas to Supply International Stem Cell’s Products in Japan

  • International Stem Cell (ISCO) granted Veritas distribution rights for its human cell culture products throughout Japan. The deal was signed through International Stem Cell’s wholly owned subsidiary, Lifeline Cell Technology.

    Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells, including products to culture primary human cells and human stem cells. This agreement marks the first step in Lifeline’s plan to meet requests from Japan, Korea, and India.

    Lifeline points out that its products are used for clinical applications and in academic, government, and pharmaceutical research laboratories. ISCO has also developed human parthenogenetic stem cell lines (hpSC). The firm believes that hpSCs could potentially minimize the rejection of transplanted cells by a patient’s immune system as well as avoid the ethical issues that are stifling research with embryonic stem cells.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »